Видео ютуба по тегу Biocon Group Growth Outlook

Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Biologics CEO: Integration To Boost Value, Balance Sheet & Competitiveness | Business News
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Appoints Peter Bains As Group CEO To Drive 'Synergistic' Growth: What's The Road Ahead?
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Biocon Biologics reports A 29% YoY Growth For Q1FY23 With Revenues At ₹977 Cr
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
Strong Biosimilar Growth Powers Biocon | Trading Hour | CNBC TV18
CEO of India's Biocon discusses first-quarter results
CEO of India's Biocon discusses first-quarter results
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Q4: Muted Growth In Generic Business | Review By Kiran Mazumdar Shaw | Business News
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Biocon Income Analysis | Stock Analysis 2025 | Revenue, Profit Trends, EPS Growth & Pharma Outlook
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Why Are Analysts Betting On Biocon Shares? Detailed Analysis On Know Your Company | NDTV Profit
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn
How Biocon Is Driving Market Expansion
How Biocon Is Driving Market Expansion
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Biologics Q3: Biosimilars Revenue Up 54%, EBITDA Up 53% YoY
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Sees Two Segments Driving Its Growth In 2019-20: #Q1WithBQ
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon Biologics Q4 Result 2025: PAT Jumps 2.5x, Demand & Price Environment Outlook | Business News
Biocon's Kiran Mazumdar Shaw Discusses Biosimilar Opportunities, 2023 Outlook | CNBC-TV18
Biocon's Kiran Mazumdar Shaw Discusses Biosimilar Opportunities, 2023 Outlook | CNBC-TV18
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Biosimilars Consolidation Rationale! Eye On Capex Cycle, R&D Costs & Global Play | Business
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Management On Q1 Result And Growth Strategy For FY22
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon
Biocon Ltd concall for Q2FY26 #Bioconconcall #Biocon
Biocon Launches Generic Liraglutide In UK | Siddharth Mittal On Margins Outlook & FY26 Guidance
Biocon Launches Generic Liraglutide In UK | Siddharth Mittal On Margins Outlook & FY26 Guidance
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report
Biocon's Kiran Mazumdar Shaw On Strong Q4, Biosimilar Business & FY24 Outlook | Halftime Report